TrialNature communications2026

Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.

Steven David et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.